Treprostinil Uses, Dosage, Side Effects and Interactions
Orenitram
Orenitram came 11 years after Remodulin (December 2013) as an extended-release tablet, a form not listed for Remodulin. No generic is listed as extended-release tablets, though generic treprostinil is listed as injections.
Tyvaso
Tyvaso came 7 years after Remodulin (July 2009) as an inhalation solution (nebulizer), a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.
Remodulin
Remodulin was the first treprostinil product the FDA approved, in May 2002. An FDA-approved generic with the same active ingredient is listed.
Yutrepia
Yutrepia came 23 years after Remodulin (May 2025) as an inhalation powder, a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.
Tyvaso DPI
Tyvaso DPI came 20 years after Remodulin (May 2022) as an inhalation powder, a form not listed for Remodulin. No generic is listed as inhalers, though generic treprostinil is listed as injections.
Treprostinil is a prostacyclin-based medicine used to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), available in inhaled, oral, and injectable forms.
Quick links
Ask Anything About TreprostinilType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Treprostinil in Short
- Drug class Prostacycline Vasodilator How the FDA classifies it
What it treatsTreprostinil treats pulmonary arterial hypertension (PAH; WHO Group 1) — high blood pressure in the arteries of the lungs. Depending on the product and route, it is used to improve exercise ability, delay disease progression, or reduce symptoms tied to physical activity.
- How you get it Prescription only
- Comes asInjection, extended-release tablet and inhalerAvailable strengths
Injection (into a vein, under the skin)
- 8 mg/20 mL
- 20 mg/20 mL
- 50 mg/20 mL
- 100 mg/20 mL
- 200 mg/20 mL
Extended-release tablet (by mouth)
- 0.125 mg
See forms and strengths+ 14 more strengthsShow fewer strengths
Extended-release tablet (by mouth)
- 0.25 mg
- 1 mg
- 2.5 mg
- 5 mg
Inhaler (by mouth, inhaled)
- 16 mcg
- 26.5 mcg
- 32 mcg
- 48 mcg
- 53 mcg
- 64 mcg
- 79.5 mcg
- 80 mcg
- 106 mcg
- 1.74 mg/2.9 mL
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Orenitram (tablet, extended release)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs292 interact 5 major, 261 moderate and 26 minor
- What Medicaid pays
- Orenitram (brand)$8.17 to $307.42 a tablet
- Injections and inhalers: no national price found
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Treprostinil is a specialist medicine for pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries) and, in inhaled form, for pulmonary hypertension from interstitial lung disease (lung scarring). It copies a natural substance called prostacyclin to widen lung blood vessels and slow platelets (clotting cells) from clumping, and it has been used since about 2002, with FDA-approved generics listed. Side effects are common, mainly headache, flushing, jaw pain and nausea, plus pain at the site with infusions under the skin. Above all, never let it stop suddenly, since PAH can worsen fast, and with IV use treat fever or chills as an urgent sign of bloodstream infection.
Key Takeaways From the HelloPharmacist Team
- Expect inhaler sessions several times daily, tablets with food two or three times daily, or a nonstop infusion pump, depending on your form.
- Order refills early and keep backup supplies on hand, because running out even briefly can make PAH worsen quickly.
- Get help right away for fainting, marked dizziness or unusual bleeding, since it lowers blood pressure and blunts platelet clumping.
- Tell your team before starting gemfibrozil or rifampin, which raise or lower treprostinil levels, and about any blood pressure medicines.
Patient Information Guide for Treprostinil
What It’s Used For
Treprostinil is approved for use across several products and routes. Here is the full set of supported indications:
- Pulmonary arterial hypertension (PAH; WHO Group 1) — improving exercise ability: Supported by Tyvaso, Tyvaso DPI, Yutrepia (inhaled), and treprostinil injection / Remodulin (subcutaneous or IV)
- PAH (WHO Group 1) — delaying disease progression and improving exercise capacity: Orenitram (extended-release oral tablet) only
- PAH (WHO Group 1) — transitioning patients from epoprostenol: Treprostinil injection and Remodulin only
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) — improving exercise ability: Tyvaso, Tyvaso DPI, and Yutrepia (inhaled forms) only
How It Works
Treprostinil mimics a natural substance in the body called prostacyclin. It works by directly relaxing and widening the blood vessels in the lungs and throughout the body, which lowers the pressure the heart has to pump against. It also reduces the tendency of platelets (the tiny blood cells that form clots) to clump together, and may help slow the abnormal thickening of blood vessel walls that characterizes PAH.
Drug Class
Drug Class
- Prostacycline Vasodilator
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Prostacycline Vasodilator
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Treprostinil in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)- Vasodilation
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Prostaglandins I
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Platelet aggregation inhibitors excl. heparin
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
How treprostinil is taken varies significantly by product — always follow your prescriber's specific instructions.
- Orenitram (tablet): Taken by mouth with food, multiple times per day; tablets must be swallowed whole
- Tyvaso (inhaled solution): Inhaled using the Tyvaso Inhalation System in 4 sessions per day, spaced about 4 hours apart during waking hours
- Tyvaso DPI (inhaled powder): Inhaled using the Tyvaso DPI Inhaler in 4 sessions per day, approximately 4 hours apart
- Yutrepia (inhaled capsule): Inhaled — not swallowed — using the supplied device, 3 to 5 times per day
- Remodulin / treprostinil injection: Given as a continuous infusion under the skin or into a vein, around the clock; doses are increased gradually
Never stop treprostinil suddenly or miss large portions of your dose without speaking to your doctor first — abrupt changes can be dangerous.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Treprostinil Injection
Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults new to prostacyclin infusion therapy · Starting dose 1.25 ng/kg/min continuous subcutaneous or intravenous infusion; if not tolerated because of systemic effects, reduce to 0.625 ng/kg/min
Good to know
Subcutaneous preferred; IV if subcutaneous not tolerated
IV means given into a vein (intravenous).
Adults switching from epoprostenol · Step 1 Remodulin 10% Starting Epoprostenol Dose; epoprostenol unchanged
Good to know
In a hospital with constant observation
Adults with mild or moderate liver problems · Starting dose Decrease initial dose to 0.625 ng/kg/min ideal body weight
Good to know
Not studied in severe hepatic insufficiency
Treprostinil Taken by Mouth
Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults · Starting dose · Three times Starting dose 0.125 mg three times a day Highest dose 120 mg a day
Step by step
- 0.125 mg three times daily with food, about 8 hours apart
- Titrate by 0.125 mg three times daily not more often than every 3 to 4 days
Good to know
Swallow whole with food
Adults · Starting dose · Twice Starting dose 0.25 mg twice a day Highest dose 120 mg a day
Step by step
- 0.25 mg twice daily with food, about 12 hours apart
- Titrate by 0.25 or 0.5 mg twice daily not more often than every 3 to 4 days
Good to know
Swallow whole with food
Adults with mild liver problems or taking strong CYP2C8 inhibitors · Starting dose Starting dose 0.125 mg twice a day
- Start at 0.125 mg twice daily, with 0.125 mg twice daily increments not more often than every 3 to 4 days
Good to know
Avoid in moderate impairment; contraindicated in severe
Tyvaso DPI
Pulmonary arterial hypertension or lung high blood pressure from lung scarring disease
Adults · Starting dose Starting dose 16 mcg 4 times a day
- One 16 mcg cartridge per treatment session, 4 times daily, about 4 hours apart
- Single inhalation per cartridge
Adults · Maintenance dose Usual dose 48 mcg to 64 mcg 4 times a day
- Increase by 16 mcg per session at about 1- to 2-week intervals
- Target 48 mcg to 64 mcg per session, 4 times daily
Yutrepia
Pulmonary arterial hypertension (high blood pressure in the lungs)
Adults new to treprostinil Starting dose 26.5 mcg 3 to 5 times a day Usual dose 79.5 mcg to 106 mcg 4 times a day
Step by step
- 26.5 mcg 3 to 5 times per day, in 2 breaths
- Increase by 26.5 mcg per dose each week as tolerated
- Target 79.5 mcg to 106 mcg 4 times daily
- Doses above 848 mcg per day have not been studied
Adults switching from Tyvaso · 5 or less breaths Starting dose 26.5 mcg 3 to 5 times a day
- 26.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 6 to 8 breaths Starting dose 53 mcg 3 to 5 times a day
- 53 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 9 to 11 breaths Starting dose 79.5 mcg 3 to 5 times a day
- 79.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 12 to 14 breaths Starting dose 106 mcg 3 to 5 times a day
- 106 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 15 to 17 breaths Starting dose 132.5 mcg 3 to 5 times a day
- 132.5 mcg, 3 to 5 times per day, in 2 breaths
Adults switching from Tyvaso · 18 or more breaths Starting dose 159 mcg 3 to 5 times a day
- 159 mcg, 3 to 5 times per day, in 2 breaths
Tyvaso
Pulmonary arterial hypertension or lung high blood pressure from lung scarring disease
Adults · Starting dose Starting dose 3 breaths (18 mcg) 4 times a day
- 3 breaths (18 mcg) per treatment session, 4 times daily
- If not tolerated, reduce to 1 or 2 breaths
Side Effects
Side effects vary by route, but here are the most commonly reported ones across treprostinil products:
Common side effects
- Infusion site pain and skin reaction (with injectable forms)
- Headache
- Diarrhea
- Nausea
- Jaw pain
- Flushing or vasodilation (feeling of warmth, skin redness)
- Swelling (edema)
- Low blood pressure (hypotension)
- Rash
When to get medical help
- Call your doctor or seek emergency care if you develop signs of a bloodstream infection: fever, chills, or feeling very unwell — especially with IV infusion
- Do not suddenly stop or sharply reduce your dose; this can cause a rapid worsening of PAH symptoms
- Get immediate help if you feel faint, dizzy, or have a significant drop in blood pressure
- Tell your doctor right away if you notice unusual or prolonged bleeding, as treprostinil affects platelet function
- Seek care promptly for any signs of severe infection at the catheter or infusion site
Warnings and Precautions
- Risk of serious bloodstream infection with IV use: Long-term IV infusion through a central venous catheter carries a risk of life-threatening blood infections and sepsis. Subcutaneous infusion is preferred for this reason. Watch for fever, chills, or sudden worsening and seek care immediately.
- Never stop abruptly: Suddenly stopping or sharply reducing the dose can cause a rapid, dangerous worsening of PAH symptoms. Any dose changes must be made with medical guidance.
- Low blood pressure risk: Treprostinil widens blood vessels throughout the body, which can cause symptomatic low blood pressure — especially in patients who already have low systemic blood pressure.
- Increased bleeding risk: Because treprostinil inhibits platelet aggregation (clumping), it can increase the tendency to bleed. Report unusual bruising or bleeding to your doctor.
- Liver disease caution: In patients with liver problems, treprostinil clears much more slowly, leading to higher drug levels and greater risk of side effects. Dose must be adjusted carefully; use is contraindicated in severe liver impairment.
Interactions
Treprostinil can be affected by certain other medicines — tell your prescriber and pharmacist everything you take:
- Gemfibrozil (cholesterol medicine): Blocks the liver enzyme (CYP2C8) that clears treprostinil, roughly doubling drug levels — a significant interaction requiring medical attention
- Rifampin (antibiotic): Speeds up treprostinil clearance through the same enzyme, reducing how much is in your body and potentially making it less effective
- Blood pressure medicines and other vasodilators: Can add to treprostinil's blood pressure-lowering effect, increasing the risk of hypotension
- Warfarin (blood thinner): Treprostinil does not appear to change warfarin levels or its INR effect, but treprostinil's own platelet-inhibiting action means bleeding risk should still be monitored
- Bosentan and sildenafil: No significant pharmacokinetic interaction found in studies; these are frequently prescribed alongside treprostinil but your full medicine list should always be reviewed by your care team
Interactions Listed in the FDA-Approved Label
From the Treprostinil prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
What happensNo pharmacokinetic interactions between treprostinil and bosentan were observed.
-
What happensNo pharmacokinetic interactions between treprostinil and sildenafil were observed.
-
What happensIncreases exposure (Cmax and AUC) to oral treprostinil.What to doWith strong CYP2C8 inhibitors, oral initial dose is 0.125 mg BID.
-
What happensDecreases exposure to treprostinil.
-
What happensNo clinically significant effect on treprostinil pharmacokinetics.
-
What happensNo effect on warfarin pharmacokinetics or INR; no clinically significant effect on treprostinil.
-
What happensNo clinically significant effect on treprostinil pharmacokinetics.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Treprostinil injection dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn. 7.1 Effect of CYP2C8 Inhibitors and Inducers on Treprostinil Dose adjustment of treprostinil may be necessary when co-administered with CYP2C8 inducers or inhibitors. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both C max and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It has not been determined if the changes in exposure of treprostinil with inhibitors or inducers of CYP2C8 observed for the oral administration of treprostinil would be similar for treprostinil administered via the parenteral route.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Severe liver impairment (Child-Pugh Class C): Treprostinil is contraindicated — it cannot be used safely
- Moderate liver impairment: Orenitram should be avoided; other forms require extra caution and lower starting doses
- Mild liver impairment: Use with caution; lower starting doses and slow titration are required
- Pregnancy: Animal studies showed fetal harm at relatively low doses; PAH in pregnancy itself carries serious risks to mother and baby — discuss risks and benefits carefully with your doctor before or if you become pregnant
- Breastfeeding: It is unknown whether treprostinil passes into human milk; discuss with your doctor
- Children: Safety and effectiveness have not been established in pediatric patients
- Older adults: Higher rates of side effects have been observed; dose selection should be cautious, accounting for possible reduced liver or heart function
- Kidney disease: No dose adjustment is required; treprostinil is not removed by dialysis
Overdose
Too much treprostinil causes an exaggerated version of its normal effects: flushing, headache, low blood pressure, nausea, vomiting, and diarrhea. In serious cases — particularly if a large accidental dose is delivered through an IV catheter — severe low blood pressure, near-fainting, or seizure-like activity can occur. Most overdose events in clinical trials resolved when the infusion was slowed or stopped. If you suspect an overdose, seek emergency medical care immediately.
Half-Life and How Your Body Processes It
When given by subcutaneous infusion, treprostinil is almost completely absorbed, reaching steady drug levels in roughly 10 hours. It is about 91% bound to proteins in the blood and is broken down primarily in the liver by an enzyme called CYP2C8. Most of the drug and its inactive breakdown products leave the body through the urine. The drug's half-life — the time it takes for the body to clear half of it — is approximately 4 hours after subcutaneous dosing. In patients with liver disease, clearance can be reduced by up to 80%, causing drug levels to build much higher than normal.
Storage
Stored at 25°C (77°F), with excursions permitted to 2° to 30°C (36° to 86°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Treprostinil
From the licensed clinical database we use, rolled up per supplement, most serious first.292 supplements and herbal products have documented interactions with Treprostinil in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 5Major
- 261Moderate
- 26Minor
- ACTIVATED CHARCOALMajor
- AMERICAN HELLEBOREMajor
- AMERICAN MISTLETOEMajor
- PIRACETAMMajor
- TYRAMINEMajor
- 7,8-BENZOFLAVONEModerate
- ACONITEModerate
- ADRAFINILModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrients Treprostinil May Deplete
Nutrients Treprostinil has been linked with lower levels of, from the licensed clinical database we use.Treprostinil has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur. It means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines), not medical advice. Do not start or stop medications or supplements without professional guidance.
Treprostinil: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Treprostinil — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is treprostinil and why did my doctor prescribe it?
I'm on the inhaled version — how often do I need to use it each day?
What side effects should I expect, and which ones mean I need to call someone?
Can I ever just stop taking it if I feel like I need a break?
Are there medicines or supplements I should avoid while taking treprostinil?
Is it safe to get pregnant or breastfeed while on treprostinil?
Is treprostinil available over the counter?
When was treprostinil first available?
Who makes treprostinil?
What is the brand name of treprostinil?
What is the generic name of Orenitram?
What drug class is treprostinil?
Is there a generic version of treprostinil?
What strengths does treprostinil come in?
How much does treprostinil cost?
Is there a treprostinil shortage?
Where can I read the treprostinil prescribing information (package insert)?
Can you crush treprostinil?
Is treprostinil gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Treprostinil
Skip the scrolling. Ask in your own words and get an answer from Treprostinil’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Treprostinil’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Treprostinil on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Treprostinil Forms and Strengths (How It Comes)
Treprostinil comes in 3 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Treprostinil inactive ingredients by manufacturer.
Injection
How this form is used
- Remodulin and treprostinil injection are used to treat PAH (WHO Group 1) to reduce symptoms associated with exercise
- Remodulin and treprostinil injection are used in PAH patients who need to transition from epoprostenol, to slow the rate of disease worsening
- Remodulin and treprostinil injection are given as a continuous infusion — subcutaneous (under the skin) is the preferred route; intravenous (into a vein) is used when subcutaneous is not tolerated
- Remodulin may be diluted with Sterile Diluent for Remodulin or a similar approved high-pH glycine diluent; treprostinil injection may be diluted with Sterile Diluent for Treprostinil or a similar approved diluent
- Doses are started low and increased gradually based on response — never stop or sharply reduce the infusion suddenly
- When transitioning from epoprostenol, Remodulin or treprostinil injection dose is increased slowly while epoprostenol is decreased, under close medical supervision
Extended-release tablet
How this form is used
- Orenitram is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to delay disease progression and improve exercise capacity
- Orenitram was studied mainly in patients with WHO functional class II–III PAH symptoms
- Orenitram must be taken with food every time
- Swallow Orenitram tablets whole — do not crush, split, or chew them
- Orenitram is typically taken multiple times per day; doses are spaced several hours apart as directed by your prescriber
- If transitioning from IV or subcutaneous Remodulin, Orenitram dose is increased while the infusion is gradually decreased — do not manage this transition on your own
Inhaler
How this form is used
- Tyvaso is used to treat pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
- Tyvaso is used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability
- Tyvaso DPI is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
- Yutrepia is used to treat PAH (WHO Group 1) and PH-ILD (WHO Group 3) to improve exercise ability
- Tyvaso is used only with the Tyvaso Inhalation System device and is administered in 4 separate sessions per day, spaced approximately 4 hours apart during waking hours
- Tyvaso DPI is used only with the Tyvaso DPI Inhaler; each cartridge delivers one inhalation, and treatment is given in 4 sessions per day roughly 4 hours apart
- Yutrepia capsules are for inhalation only using the supplied inhaler — do not swallow them; they are administered 3 to 5 times per day, with each capsule's contents inhaled in 2 breaths
- Timing of inhaled sessions can be adjusted around planned activities, as effects diminish over the dosing interval
Show 4 more strengths Show fewer strengths
Treprostinil on the U.S. Market: Products, Makers and Brands
How Treprostinil appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
6 companies list 52 Treprostinil product records with the FDA, mostly as injection, extended-release tablet, inhaler; the earliest marketing or approval year on record is 2002. Brand names in the directory today include Orenitram, Tyvaso, Remodulin and 2 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (19) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Treprostinil Is Used (Medicaid Data)
How many Treprostinil prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Treprostinil prescribed? Of the 1,682 medications we measure, Treprostinil ranks #863 by Medicaid prescriptions — more than 49% of them.
Utilization by Treprostinil product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
treprostinil 10 MG/ML Injectable Solution Most dispensed
1 of 6 listed NDCs had Medicaid claims. RxNorm 349408
treprostinil 5 MG/ML Injectable Solution
2 of 6 listed NDCs had Medicaid claims. RxNorm 349410
treprostinil 1 MG/ML Injectable Solution
2 of 6 listed NDCs had Medicaid claims. RxNorm 349407
treprostinil 0.6 MG/ML Inhalation Solution
1 of 4 listed NDCs had Medicaid claims. RxNorm 857795
12 HR treprostinil 1 MG Extended Release Oral Tablet
1 of 3 listed NDCs had Medicaid claims. RxNorm 1488674
treprostinil 0.064 MG Inhalation Powder
1 of 3 listed NDCs had Medicaid claims. RxNorm 2602764
12 HR treprostinil 0.25 MG Extended Release Oral Tablet
1 of 3 listed NDCs had Medicaid claims. RxNorm 1488670
12 HR treprostinil 5 MG Extended Release Oral Tablet
1 of 3 listed NDCs had Medicaid claims. RxNorm 1858831
treprostinil 2.5 MG/ML Injectable Solution
1 of 6 listed NDCs had Medicaid claims. RxNorm 349409
12 HR treprostinil 2.5 MG Extended Release Oral Tablet
1 of 3 listed NDCs had Medicaid claims. RxNorm 1488678
treprostinil 0.048 MG Inhalation Powder
1 of 3 listed NDCs had Medicaid claims. RxNorm 2602760
12 HR treprostinil 0.125 MG Extended Release Oral Tablet
1 of 3 listed NDCs had Medicaid claims. RxNorm 1488665
treprostinil 0.032 MG Inhalation Powder
1 of 3 listed NDCs had Medicaid claims. RxNorm 2602756
treprostinil 0.016 MG Inhalation Powder
1 of 3 listed NDCs had Medicaid claims. RxNorm 2602751
treprostinil 0.0795 MG Inhalation Powder
1 of 1 listed NDCs had Medicaid claims. RxNorm 2714670
treprostinil 0.106 MG Inhalation Powder
1 of 1 listed NDCs had Medicaid claims. RxNorm 2714674
treprostinil 0.053 MG Inhalation Powder
1 of 1 listed NDCs had Medicaid claims. RxNorm 2714666
treprostinil 0.0265 MG Inhalation Powder
1 of 1 listed NDCs had Medicaid claims. RxNorm 2714659
Other Treprostinil products: packs and listings not matched to one strength and form
3 of 74 listed NDCs had Medicaid claims.
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 23 of the 133 listed Treprostinil NDCs had Medicaid claims.
Compare Treprostinil Products
A representative set of FDA-listed product records for Treprostinil — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Extended-release tablet | ||||
| 0.125 mg | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 0.25 mg | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 1 mg | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 2.5 mg | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 5 mg | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 💊Inhaler | ||||
| 26.5 mcg | Respiratory (inhalation) | Liquidia Technologies, Inc. | NDA | View NDC → |
| 53 mcg | Respiratory (inhalation) | Liquidia Technologies, Inc. | NDA | View NDC → |
| 79.5 mcg | Respiratory (inhalation) | Liquidia Technologies, Inc. | NDA | View NDC → |
| 106 mcg | Respiratory (inhalation) | Liquidia Technologies, Inc. | NDA | View NDC → |
| 16 mcg | Oral | United Therapeutics Corporation × 2 listings | NDA | View NDC → |
| 32 mcg | Oral | United Therapeutics Corporation × 2 listings | NDA | View NDC → |
| 48 mcg | Oral | United Therapeutics Corporation × 2 listings | NDA | View NDC → |
| 64 mcg | Oral | United Therapeutics Corporation × 2 listings | NDA | View NDC → |
| 80 mcg | Oral | United Therapeutics Corporation × 2 listings | NDA | View NDC → |
| 1.74 mg/2.9 mL | Oral | United Therapeutics Corporation | NDA | View NDC → |
| 💊Injection | ||||
| 20 mg/20 mL | Intravenous, Subcutaneous | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 50 mg/20 mL | Intravenous, Subcutaneous | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous, Subcutaneous | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 200 mg/20 mL | Intravenous, Subcutaneous | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 20 mg/20 mL | Intravenous, Subcutaneous | Dr.Reddy's Laboratories Inc., | ANDA | View NDC → |
| 50 mg/20 mL | Intravenous, Subcutaneous | Dr.Reddy's Laboratories Inc., | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous, Subcutaneous | Dr.Reddy's Laboratories Inc., | ANDA | View NDC → |
| 200 mg/20 mL | Intravenous, Subcutaneous | Dr.Reddy's Laboratories Inc., | ANDA | View NDC → |
| 20 mg/20 mL | Intravenous, Subcutaneous | Sandoz Inc | ANDA | View NDC → |
| 50 mg/20 mL | Intravenous, Subcutaneous | Sandoz Inc | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous, Subcutaneous | Sandoz Inc | ANDA | View NDC → |
| 200 mg/20 mL | Intravenous, Subcutaneous | Sandoz Inc | ANDA | View NDC → |
| 20 mg/20 mL | Intravenous, Subcutaneous | Teva Parenteral Medicines, Inc. | ANDA | View NDC → |
| 50 mg/20 mL | Intravenous, Subcutaneous | Teva Parenteral Medicines, Inc. | ANDA | View NDC → |
| 100 mg/20 mL | Intravenous, Subcutaneous | Teva Parenteral Medicines, Inc. | ANDA | View NDC → |
| 200 mg/20 mL | Intravenous, Subcutaneous | Teva Parenteral Medicines, Inc. | ANDA | View NDC → |
| 8 mg/20 mL | Intravenous, Subcutaneous | United Therapeutics Corporation | NDA | View NDC → |
| 20 mg/20 mL | Intravenous, Subcutaneous | United Therapeutics Corporation | NDA | View NDC → |
| 50 mg/20 mL | Intravenous, Subcutaneous | United Therapeutics Corporation | NDA | View NDC → |
| 100 mg/20 mL | Intravenous, Subcutaneous | United Therapeutics Corporation | NDA | View NDC → |
| 200 mg/20 mL | Intravenous, Subcutaneous | United Therapeutics Corporation | NDA | View NDC → |
| 💊Kits | ||||
| — | — | United Therapeutics Corporation × 11 listings | NDA | View NDC → |
Showing 52 of 52 products — FDA National Drug Code Directory. See every product, package size and price: browse all 52 Treprostinil NDCs →
Treprostinil Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Treprostinil — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Treprostinil in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Treprostinil FDA Approval History
How Treprostinil went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Treprostinil Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Treprostinil recalls since July 2021.
✅No Treprostinil recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Treprostinil in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 4
- Strengths
- 20
- Forms in current FDA listings
- 2 of 4
RxCUI 343048 -
Dose form (SCDF) Inhalation PowderNo current FDA listing
RxCUI 2602750 -
Dose form (SCDF) Inhalation SolutionNo current FDA listing
RxCUI 2108557Its strength (SCD)-
0.6 mg/mL
RxCUI 857795
-
0.6 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Treprostinil Supply and Shortage Status
Whether Treprostinil is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Medicaid Pays for Treprostinil
CMS’s weekly pharmacy survey (NADAC) has no price for Treprostinil, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.
No price was found for Treprostinil injections or inhalers, so the prices below are for the extended-release tablets only.
| Form | Strength | Version | What Medicaid paid | |
|---|---|---|---|---|
| Extended-release tablet · Oral | 0.125 mg | Orenitram (brand) | $8.17 per tablet | NDC details & Medicaid use |
| Extended-release tablet · Oral | 0.25 mg | Orenitram (brand) | $15.60 per tablet | NDC details & Medicaid use |
| Extended-release tablet · Oral | 1 mg | Orenitram (brand) | $60.20 per tablet | NDC details & Medicaid use |
| Extended-release tablet · Oral | 2.5 mg | Orenitram (brand) | $155.32 per tablet | NDC details & Medicaid use |
| Extended-release tablet · Oral | 5 mg | Orenitram (brand) | $307.42 per tablet | NDC details & Medicaid use |
Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.
Treprostinil Brand Names
Treprostinil has 5 brand names on record: Orenitram, Tyvaso, Remodulin, Yutrepia and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Treprostinil: Manufacturers and Labelers
6 companies list Treprostinil products with the FDA. By number of product records, the largest are United Therapeutics Corporation, Alembic Pharmaceuticals Inc., Dr.Reddy's Laboratories Inc.,. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Treprostinil Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Alembic Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →